S2427: Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)

Study of Investigational Immunoradiotherapy for Muscle Invasive Bladder Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

This study investigates muscle invasive bladder cancer. It examines the effects of combining treatments after initial therapy.

This study evaluates how well the combination of treatments works in preventing the need for bladder removal.

  • Who can participate: Eligibility criteria are to be determined.
  • Study details: Participants will receive a combination of investigational medication and radiation therapy.
Updated on 03 Aug 2026. Study ID: 26-6370
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator